P

Pinnacle Research Group | Anniston, AL

Research site
(Unclaimed)
Location
409 East 10th Street, Anniston, Alabama, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

19 of 123
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Risankizumab
Biological: Placebo

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Risankizumab
Biological: Placebo

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).

Active, not recruiting
Epstein-Barr Virus Infection
Biological: mRNA-1189
Biological: Placebo

Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage...

Enrolling
Systemic Lupus Erythematosus
Drug: DS-7011a
Drug: Placebo

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Placebo
Drug: Astegolimab

This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV...

Enrolling
Clostridium Difficile (C. Difficile)
Drug: DNV3837

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Dyslipidemias
Drug: Obicetrapib
Drug: Placebo

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and...

Active, not recruiting
Overweight or Obesity
Obese
Other: Bimagrumab Placebo
Biological: Bimagrumab

This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which c...

Enrolling
Rheumatoid Arthritis
Drug: Baricitinib
Device: Active Stimulation

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenz...

Active, not recruiting
Seasonal Influenza
Biological: Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Biological: mRNA-1010

Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relati...

Enrolling
Endometriosis
Drug: Placebo
Drug: Combined Oral Contraceptive

This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part...

Enrolling
Celiac Disease
Drug: DONQ52
Drug: Placebo

Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe R...

Active, not recruiting
Arthritis, Rheumatoid
Drug: Placebo
Drug: KPL-404

This is a phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and pharmacokinetics of ASC10 table...

Not yet enrolling
SARS CoV 2 Infection
Drug: Placebo
Drug: ASC10

Trial conditions

Arthritis (20 trials)
Rheumatoid Arthritis (18 trials)
Systemic Lupus Erythemat... (16 trials)
Type 2 Diabetes Mellitus (9 trials)
Dermatitis (8 trials)
Atopic Dermatitis (7 trials)
Diabetes Mellitus (7 trials)
Eczema (7 trials)
COVID-19 (4 trials)
Chronic Obstructive Pulm... (4 trials)

And 89 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems